537033-54-8

Basic information

• Product Name: 4-BROMO-2,6-DIFLUOROPHENYLACETIC ACID
• Synonyms: RARECHEM AL BO 2254;4-BROMO-2,6-DIFLUOROPHENYLACETIC ACID;(2,6-Difluoro-4-broMophenyl)acetic Acid;4-BroMo-2,6-difluorobenzeneacetic Acid
• CAS NO: 537033-54-8
• Molecular Formula: C₈H₅BrF₂O₂
• Molecular Weight: 251.02
• Product Categories: Aromatics;Intermediates & Fine Chemicals;Pharmaceuticals;Fluorine series
• Mol File: 537033-54-8.mol

Chemical Properties

• Boiling Point: 307.7±37.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.77
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 3.60±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-2,6-DIFLUOROPHENYLACETIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2,6-DIFLUOROPHENYLACETIC ACID(537033-54-8)
• EPA Substance Registry System: 4-BROMO-2,6-DIFLUOROPHENYLACETIC ACID(537033-54-8)

Safety Data

• Hazard Codes: Xi
• Hazardous Substances Data: 537033-54-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
4-Bromo-2,6-difluorophenylacetic acid is used as a chemical intermediate for the synthesis of various pharmaceutical compounds. Its unique structure allows for the development of new drugs with specific therapeutic properties.
Used in Agrochemical Industry:
4-Bromo-2,6-difluorophenylacetic acid is used as a key component in the preparation of pyrido[2,3-b]pyrazine-8-amine derivatives, which are known as phytopathogenic fungicides. These fungicides are effective in controlling phytopathogenic fungi that cause diseases in plants, thus playing a crucial role in agriculture for crop protection and yield enhancement.

InChI:InChI=1S/C8H5BrF2O2/c9-4-1-6(10)5(3-8(12)13)7(11)2-4/h1-2H,3H2,(H,12,13)

Upstream product

• 537033-52-6 2-(4-bromo-2,6-difluorophenyl)acetonitrile 
• 869361-54-6 4-bromo-2,6-difluorobenzyl methanesulfonate 
• 162744-59-4 (4-bromo-2,6-difluoro-phenyl)methanol 
• 183065-68-1 4-bromo-2,6-difluorobenzoic acid 
• 1426050-43-2 2-(4-bromo-2,6-difluorophenyl)acetamide 
• 162744-60-7 5-bromo-2-(bromomethyl)-1,3-difluoro-benzene 

Downstream Products

• 872089-12-8 2-(4-bromo-2,6-difluorophenyl)acetyl chloride 
• 1426050-44-3 2-(4-bromo-2,6-difluoro-phenyl)ethanol 
• 1426050-45-4 4-bromo-2,6-difluorophenethyl acetate 
• 1426050-46-5 2-bromo-2-(4-bromo-2,6-difluorophenyl)ethyl acetate 
• 1426050-47-6 2-(4-bromo-2,6-difluorophenyl)-2-(4-cyclopropyl-3-oxo-1-oxa-4,9-diazaspiro[5.5]undecan-9-yl)ethyl acetate 
• 872089-16-2 7-(4-bromo-2,6-difluoro-phenyl)-6,8-dichloro-pyrido[2,3-b]pyrazine 
• 872089-13-9 methyl 3-[2-(4-bromo-2,6-difluoro-phenyl)-acetylamino]-pyrazine-2-carboxylate 
• 872089-15-1 7-(4-bromo-2,6-difluoro-phenyl)-8-hydroxy-5H-pyrido[2,3-b]pyrazin-6-one 
• 872089-17-3 [7-(4-bromo-2,6-difluoro-phenyl)-6-chloro-pyrido[2,3-b]pyrazin-8-yl]-sec-butyl-amine 

Relevant articles and documents

NOVEL COMPOUNDS AS REARRANGED DURING TRANSFECTION (RET) INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

PYRIDINE DERIVATIVES AS REARRANGED DURING TRANSFECTION (RET) KINASE INHIBITORS

This invention relates to novel compounds which are inhibitors of the Rearranged during Transfection (RET) kinase, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy, alone or in combination, for the normalization of gastrointestinal sensitivity, motility and/or secretion and/or abdominal disorders or diseases and/or treatment related to diseases related to RET dysfunction or where modulation of RET activity may have therapeutic benefit including but not limited to all classifications of irritable bowel syndrome (IBS) including diarrhea-predominant, constipation-predominant or alternating stool pattern, functional bloating, functional constipation, functional diarrhea, unspecified functional bowel disorder, functional abdominal pain syndrome, chronic idiopathic constipation, functional esophageal disorders, functional gastroduodenal disorders, functional anorectal pain, inflammatory bowel disease, proliferative diseases such as non-small cell lung cancer, hepatocellular carcinoma, colorectal cancer, medullary thyroid cancer, follicular thyroid cancer, anaplastic thyroid cancer, papillary thyroid cancer, brain tumors, peritoneal cavity cancer, solid tumors, other lung cancer, head and neck cancer, gliomas, neuroblastomas, Von Hippel-Lindau Syndrome and kidney tumors, breast cancer, fallopian tube cancer, ovarian cancer, transitional cell cancer, prostate cancer, cancer of the esophagus and gastroesophageal junction, biliary cancer, adenocarcinoma, and any malignancy with increased RET kinase activity.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to spirocyclic piperidines according to Formula (I) and the use of spirocyclic piperidines for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of spirocyclic piperidines in the treatment of cancer.

FUNGICIDES BASED ON NITROGEN-CONTAINING HETEROCYCLES

The compound of the general formula (I), wherein W, X, Y, Z, R, R1 and R2 are defined as set forth in the specification, useful as fungicide.